TABLE 1

Characteristics of Women Undergoing Small-Intestinal Biopsy

CDInflammationNormal Mucosa With Positive CD Serology
Total17 95974552307
Year of birth, median (interquartile range)1970 (1945–1989)1951 (1933–1969)1963 (1947–1978)
Age (y) at time of biopsy
 Median (interquartile range)28 (6–52)46 (31–63)38 (23–53)
 Age 0–19, n (%)7428 (41)717 (10)459 (20)
 Age 20–39, n (%)3649 (20)2196 (29)755 (33)
 Age 40–59, n (%)3862 (22)2304 (31)740 (32)
 Age 60+, n (%)3020 (17)2238 (30)353 (15)
Calendar year at time of biopsy
 Median (interquartile range)1999 (1993–2003)2000 (1994–2004)2001 (1998–2004)
 ≤1986, n (%)1210 (7)464 (6)0 (0)
 1987–1999, n (%)8601 (48)3238 (43)819 (36)
 ≥2000, n (%)8148 (45)3753 (50)1488 (64)
Type 1 diabetesa, n (%)526 (3)59 (1)35 (2)
  • Histopathology findings indicating CD (villous atrophy, Marsh III), inflammation (Marsh I–II), and normal mucosa (Marsh 0), but with positive CD serology 180 days before and until 30 days after biopsy (antigliadin, antiendomysial, or antitransglutaminase antibodies). Controls are not included in the table because their age, sex, and calendar year distributions were identical to those of the individuals undergoing biopsy (due to matching).

  • a Type 1 diabetes as recorded in the National Patient Register by age 30 years (ICD-8/ICD-9, 250; ICD-10, E10).